UK Markets closed

4D pharma plc (DDDD.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
16.66+0.80 (+5.04%)
At close: 06:11PM GMT

4D pharma plc

9 Bond Court
5th Floor
Leeds LS1 2JZ
United Kingdom
44 11 3895 0130
https://www.4dpharmaplc.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees106

Key executives

NameTitlePayExercisedYear born
Mr. Duncan Joseph PeytonCEO & Exec. Director254kN/A1970
Dr. Alexander James Stevenson Ph.D.Chief Scientific Officer & Exec. Director218kN/A1972
Mr. John Brendan DoyleChief Financial OfficerN/AN/A1978
Ms. Fay WestonHead of Investor RelationsN/AN/AN/A
Mr. Adrian MurrayGen. Counsel (Interim)N/AN/AN/A
Mr. Glenn DouradoExec. VP of Corp. Devel.N/AN/AN/A
Ms. Lucy ChristieVP of HRN/AN/AN/A
Mr. Christophe CariteSr. VP of CMC & Process Devel.N/AN/AN/A
Ms. Imke MulderExec. VP of ResearchN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Corporate governance

4D pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.